血清胶质纤维酸性蛋白与神经丝轻链水平反映多发性硬化B细胞清除治疗下疾病进展的不同机制
研究纳入362例开始B细胞清除治疗的多发性硬化患者(1480份样本),以2861名对照者(4943份样本)建立sGFAP参考值。结果显示,治疗1年时sGFAP升高(Z评分>1)与未来PIRA风险增加相关(HR 1.80),而sNfL升高与PIRA的关联未达统计学显著(HR 1.45)。
要点
- 治疗1年时sGFAP Z评分>1与PIRA风险增加相关(HR 1.80)
- sNfL升高与PIRA的关联未达统计学显著(HR 1.45)
- 无PIRA患者sNfL年均下降0.92 Z评分单位,有PIRA者保持高位
核心结论
- B细胞清除治疗开始后sGFAP升高且sNfL未下降与未来PIRA风险增加相关。
研究设计与样本
- 纳入瑞士多发性硬化队列中362例开始B细胞清除治疗的患者(1480份样本),以2861名对照者(4943份样本)提供sGFAP参考值计算校正Z评分。
主要发现
- 治疗1年时sGFAP Z评分>1与PIRA风险增加相关(HR 1.80,95%CI 1.17-2.78,p=0.0079)。
- 治疗1年时sNfL升高与PIRA的关联未达统计学显著(HR 1.45,95%CI 0.95-2.24,p=0.0886)。
- 独立于PIRA事件,sGFAP水平每10年随访纵向增加0.49 Z评分单位(估计值0.49,95%CI 0.29-0.69,p<0.0001)。
- 发生PIRA的患者sGFAP Z评分较稳定患者高0.52 Z评分单位(0.52,95%CI 0.22-0.83,p=0.0009)。
- 有无PIRA患者的sNfL Z评分轨迹不同(交互作用p=0.0028),无PIRA者每10年平均下降0.92 Z评分单位(-0.92,95%CI -1.23至-0.60,p<0.0001),有PIRA者保持高位。
临床怎么用
- 作者认为这些发现为在开始B细胞清除治疗的多发性硬化患者中联合监测sNfL和sGFAP以预测PIRA风险提供了依据。
- 作者认为sGFAP可作为旨在影响多发性硬化进展性疾病生物学的临床试验的结局指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy (BCDT) and their capacity to prognosticate future progression independent of relapse activity (PIRA) events. METHODS: A total of 362 pwMS (1,480 samples) starting BCDT in the Swiss Multiple Sclerosis (MS) Cohort were included. sGFAP levels in 2,861 control persons (4,943 samples) provided normative data to calculate adjusted Z scores. RESULTS: Elevated sGFAP levels (Z score >1) at 1 year were associated with a higher hazard for PIRA (hazard ratio [HR]: 1.80 [95% CI: 1.17-2.78]; p = 0.0079) than elevated sNfL levels (HR, 1.45 [0.95-2.24], p = 0.0886) in a combined model. Independent of PIRA events, sGFAP levels longitudinally increased by 0.49 Z score units per 10 years follow-up (estimate, 0.49 [0.29, 0.69], p < 0.0001). In patients experiencing PIRA, sGFAP Z scores were 0.52 Z score units higher versus stable patients (0.52 [0.22, 0.83], p = 0.0009). Different sNfL Z score trajectories were found in pwMS with versus without PIRA (interaction p = 0.0028), with an average decrease of 0.92 Z score units per 10 years observed without PIRA (-0.92 [-1.23, -0.60], p < 0.0001), whereas levels in patients with PIRA remained high. INTERPRETATION: Elevated sGFAP and lack of drop in sNfL after BCDT start are associated with increased risk of future PIRA. These findings provide a rationale for combined monitoring of sNfL and sGFAP in pwMS starting BCDT to predict the risk of PIRA, and to use sGFAP as an outcome in clinical trials aiming to impact on MS progressive disease biology. ANN NEUROL 2025;97:104-115.
引用
- Benkert P, Maleska Maceski A, Schaedelin S, et al. Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis. Ann Neurol. 2024. PMID: 39411917. doi:10.1002/ana.27096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。